GSK Q3 Sales Rise 4% as Core EPS Beats Consensus by 4.2 Pence

GSK plc's third-quarter sales rose 4% at actual exchange rates and Core EPS beat consensus by 4.2 pence, as the company maintained its 2026 outlook for the year.

Sales totaled £8.887 billion, up 5% at constant exchange rates. The total was £45 million above the £8.842 billion consensus estimate.

Core EPS came to 54.6 pence, or about £0.55. That was 4.2 pence above the 50.4-pence consensus.

Specialty Medicines sales increased 15% at constant exchange rates to £3.9 billion. HIV sales rose 10% to £2.1 billion, while Respiratory, Immunology & Inflammation sales climbed 21% to £1.1 billion. Oncology sales grew 23% to £600 million. The growth rates for all four business areas are at constant exchange rates.

GSK reaffirmed its 2026 guidance, which calls for turnover growth of 3% to 5% and growth of 7% to 9% in both core operating profit and Core EPS at constant exchange rates. The company set out that outlook in its earlier 2026 guidance.